Yabao Pharmaceuticals and Primary Peptides Announce Exclusive China Partnership

BEIJING & VANCOUVER, British Columbia--()--Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange 600351), a leading pharmaceutical company in China, today announced an exclusive license with privately held Primary Peptides, Inc., to develop and commercialise innovative products targeting PTEN nuclear translocation for the treatment of stroke.

"Yabao is pleased to be collaborating with Primary Peptides, a world leader in development of new peptide therapeutics in the cardiovascular and neuroscience areas"

Under the terms of the agreement, Yabao receives exclusive rights to develop and commercialise in China, Taiwan and Hong Kong while Primary Peptides retains rights in all other markets. Financial terms were not disclosed.

"Yabao is pleased to be collaborating with Primary Peptides, a world leader in development of new peptide therapeutics in the cardiovascular and neuroscience areas," commented Dr. Peng Wang, President R&D, Yabao Pharmaceutical Co. "This opportunity for Yabao to expand on leading research to develop innovative products is further evidence of Yabao's growing commitment to partner the best science to treat serious diseases in China."

Dr. Max Cynader at Primary Peptides said, "We are pleased to combine our expertise in early innovative drug discovery with the significant resources that Yabao Pharmaceutical Co. can bring to developing groundbreaking new medicines. Brain protection following stroke represents a large unmet medical need, and this new peptide therapeutic has the potential to improve the lives of many stroke victims."

About Yabao Pharmaceutical Co.

Yabao Pharmaceutical Co. (Shanghai Stock Exchange 600351) is a leading China pharmaceutical company with fully-integrated development, manufacturing, and commercialization in China. Yabao is recently pursuing strategic development of innovative pharmaceuticals in addition to Yabao's well-established business in modern traditional Chinese medicines and chemical generics. In addition to strong clinical and regulatory capabilities, Yabao has strong capabilities in formulation and API production and meets good manufacturing practice (cGMP) requirements with two manufacturing sites approved by U.S. FDA and a European agency, respectively. For more information about Yabao Pharmaceutical Co., please visit www.yabao.com.cn

About Primary Peptides

Primary Peptides is a development stage biotech company that has developed a proprietary platform technology enabling it to identify, target, and disrupt specific protein-protein interactions leading to new peptide therapeutics for unmet medical needs. Our peptides can also replace SiRNA in many indications with improved pharmacokinetics and specificity. Primary Peptides has developed lead compounds in several neuroscience and cardiovascular indications.


Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.